Interview with Dr. Jennifer Cullen at ESMO 2014
Genomic health developed panel was validated in their cohort not to replace PSA but predict biochemical recurrence, metastases and death of prostate cancer. The gene panel will not replace PSA for the early diagnosis but will help predict the risk of progression in the individual patient. The 17-gene panel (oncotype-DX) is used in conjunction with available clinical predictors such as stage and Gleason grade. The 17-gene panel predicted equally well in Caucasian and African-Americans.
